Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025)
Tyra Biosciences' (TYRA) quarterly Total Non-Current Liabilities came in at $23.4 million in Q4 2025, up 14.84% YoY from $20.4 million in Q4 2024, and up 9.79% on a QoQ basis from $21.3 million in Q3 2025.
Tyra Biosciences (TYRA) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
Tyra Biosciences (TYRA) has 6 years of Total Non-Current Liabilities data on file, last reported at $23.4 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 14.84% year-over-year to $23.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.4 million (up 14.84% YoY) and the FY2025 annual result came in at $23.4 million, up 14.84% from the prior year.
- Total Non-Current Liabilities advanced to $23.4 million in Q4 2025, from $21.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $23.4 million in Q4 2025 to a low of $4.6 million in Q4 2021.
- A 5-year average of $14.0 million and a median of $15.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 163.34% in 2023, down 18.15% in 2023.
- Tracing TYRA's Total Non-Current Liabilities over 5 years: stood at $4.6 million in 2021, then surged by 78.01% to $8.2 million in 2022, then surged by 163.34% to $21.5 million in 2023, then retreated by 5.31% to $20.4 million in 2024, then rose by 14.84% to $23.4 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $23.4 million (Q4 2025), $21.3 million (Q3 2025), and $19.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.43 Mn |
| Sep 30, 2025 | 21.34 Mn |
| Jun 30, 2025 | 19.35 Mn |
| Mar 31, 2025 | 19.94 Mn |
| Dec 31, 2024 | 20.40 Mn |
| Sep 30, 2024 | 18.29 Mn |
| Jun 30, 2024 | 16.40 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Dec 31, 2023 | 21.55 Mn |
| Sep 30, 2023 | 16.11 Mn |
| Jun 30, 2023 | 11.33 Mn |
| Mar 31, 2023 | 6.13 Mn |
| Dec 31, 2022 | 8.18 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 4.60 Mn |
| Sep 30, 2021 | 5.81 Mn |
| Dec 31, 2020 | 1.86 Mn |